Lamisil Uno (Terbinafine)

Terbinafine blocks the fungal enzyme squalene epoxidase, which is essential for producing ergosterol, a key component of the fungal cell membrane. Inhibition leads to toxic squalene buildup and loss of membrane integrity, causing fungal cell death and resolution of the infection.

The dosage of Lamisil Uno is determined by the prescribing healthcare professional based on the type and extent of the infection. The prescriber will specify the amount of cream to apply, the frequency of application, and the duration of therapy.

Safety data for topical terbinafine during pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Lamisil Uno.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism—blocking squalene epoxidase rather than inhibiting lanosterol 14α‑demethylase. This often results in faster clinical cure rates for dermatophyte infections and a lower potential for drug‑drug interactions when used topically.

Lamisil Uno should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and effectiveness.

The cream is applied to clean, dry skin on the affected area. A thin layer is spread gently and rubbed in until fully absorbed. The prescriber will advise how often to apply—typically once or twice daily—and for how many days, depending on the infection.

Although rare, serious adverse reactions can include severe allergic responses such as angioedema, anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis. Immediate medical attention is required if signs of a severe skin reaction or systemic allergy develop.

Lamisil Uno should not be used by individuals with a known hypersensitivity to terbinafine or any component of the formulation. It is also contraindicated on broken or severely inflamed skin, and caution is advised in patients with significant liver disease.